USPTO Patent Application for Tau Phospho Binding Antibodies
Summary
The USPTO has published a patent application (US20260079168A1) for Tau phospho binding antibodies and antigen binding fragments thereof. The application, filed on September 15, 2025, relates to methods for detecting Tau phospho (Thr217) and potential diagnostic or therapeutic uses for diseases associated with it.
What changed
This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, specifically US20260079168A1, filed on September 15, 2025. The application details "TAU PHOSPHO (THR217) BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF," including their use in detecting Tau phospho (Thr217) and potential applications in diagnosing or treating diseases associated with this biomarker.
As this is a patent application publication, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in diagnostic and therapeutic technologies related to Tau phospho (Thr217), which may be relevant for pharmaceutical companies, medical device makers, and healthcare providers involved in Alzheimer's disease research or diagnostics.
Archived snapshot
Mar 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TAU PHOSPHO (THR217) BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
Application US20260079168A1 Kind: A1 Mar 19, 2026
Inventors
Efthalia CHRONOPOULOU, Patricia Hiroko TANI, Giovanni SUAREZ, Joseph Corey EVANS
Abstract
The technology relates in part to antibodies or antigen-binding fragments thereof that bind Tau phosphorylated at threonine 217 (Tau phospho (Thr217)) or a portion thereof, as well as methods, systems and kits for detection of Tau phospho (Thr217). In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of Tau phospho (Thr217) in a sample containing or suspected of containing Tau phospho (Thr217). In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with Tau phospho (Thr217).
CPC Classifications
G01N 33/6896 C07K 16/18 C07K 2317/33 C07K 2317/92
Filing Date
2025-09-15
Application No.
19329424
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.